



FAMPRIDINE-RELATED ATRIAL FIBRILLATION: TWO CASE REPORTS

B. TAUSTE HERNÁNDEZ¹, E. TEJEDOR TEJADA¹, I. ANDRADE ANDRADE², I. ALFEREZ GARCÍA¹.

¹HOSPITAL TORRECÁRDENAS, PHARMACY, ALMERÍA, SPAIN.

²HOSPITAL TORRECÁRDENAS, NEUROLOGY UNIT, ALMERÍA, SPAIN.

BACKGROUND AND IMPORTANCE

Fampridine (4-aminopyridine) is a drug whose indication is to improve gait in adult patients with Multiple Sclerosis with walking disability

It is important to describe adverse effects that occur in certain patients in order to prevent them in the future



RESULTS

| | SABP (mmHg) | DBP (mmHg) | Ta (°C) | SaO (%) | HR (bpm) |
|---------|-------------|------------|---------|---------|----------|
| AVERAGE | 140 | 85 | 36 | 95 | 105 |

AIM AND OBJECTIVES

To describe two cases of atrial fibrillation found in patients who were been treated with fampridine and its possible relationship with that.

- ✓ Electrocardiogram: no signs of ischemia and/or blockages in any of the cases.
- ✓ Hemogram: normalized for age.
- ✓ Biochemistry: not altered.
- ✓ Oral anticoagulants (acenocumarol) were prescribed and digoxine (0,5 mg/day) in one case.
- ✓ **Fampridine was suspended.**
- ✓ Naranjo's algorithm: "**probability**" (score of 5)
- ✓ Regional pharmacovigilance centre was notified by Yellow Card.

MATERIALS AND METHODS

- 2 patients (68 and 74 years old)
- Pathology: **Progressive Secondary Multiple Sclerosis**
- Comorbidities: **Arterial Hypertension**
- Treatment: **Fampridine 10 mg/12h**
- Both presented arrhythmic cardiorespiratory auscultation and generalized weakness
- Constants measured: SABP, DBP, Ta, SaO, HR
- Reaction causality evaluated with **Naranjo's algorithm**

CONCLUSION AND RELEVANCE

- ❖ Fampridine data sheet does not describes atrial fibrillation.
- ❖ We consider important to make a special monitoring of hypertension and heart rate in patients in treatment with Fampridine.

References and/or acknowledgements

•Fampridine®. Data sheet. The European Agency for the Evaluation of Medical Products (EMA). Committee for Proprietary Medical Products (CPMP). European Public Assessment Report (EPAR): Fampridine®

•Johnson NC1, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med. 2006 Feb;30(2):175-7.

5PSQ-074
N07 Other nervous system
drugs